About Us

Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

A Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Social Media

Bluesky • Facebook • Instagram • LinkedIn • YouTube

Meet the Laser Focus World Team

Editorial

Sales

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology
My Watchlist
Indicators
Industrial Laser Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Opportunities in IgA Nephropathy Research: Exploring the 4 Hit Process

By: StatePoint Media

photo

SPONSORED CONTENT -- (StatePoint) IgA nephropathy is a progressive, autoimmune, chronic disease that predominantly affects adults between the ages of 20 and 40, with an annual global incidence of 2.5 cases per 100,000 people. Despite its prevalence, IgA nephropathy remains a challenging disease to manage and treat.

The condition is characterized by the accumulation of immune complexes containing Gd-IgA1 in the kidneys. Over time, IgA nephropathy leads to kidney injury and can progress to kidney failure, requiring dialysis and/or kidney transplantation.

Recognizing the Patient Burden

The disease may present as asymptomatic in its early stages, but manifests in various ways, including hematuria (blood in the urine) or proteinuria (protein in the urine). Symptoms may include fatigue, backache, high blood pressure, and foamy or tea-colored urine, among others.

The impact of IgA nephropathy extends beyond the physical health of patients. As the disease progresses, patients may experience increased anxiety, impairment in daily activities, and reduced work capacity. Dr. Edgar Lerma, a leading nephrologist, explains, “Proper identification and diagnosis of IgA nephropathy are crucial, especially as patients are typically diagnosed in their 20s to 40s. Unfortunately, many will eventually progress to end-stage kidney disease, adding a physical and emotional strain not only on patients, but also on their families.”

The road to diagnosis can often be delayed, as symptoms may initially be subtle or not identified. This can lead to a delayed treatment response, further complicating disease management. As patients face progressive kidney dysfunction, identifying an effective care plan with their healthcare provider is essential.

Understanding the Treatment Landscape

Treatments may help manage symptoms and slow disease progression. Optimized supportive care today focuses on blood pressure control, renin-angiotensin system inhibition, and lifestyle modifications. In higher-risk patients, immunosuppressive therapies may be used, though they may come with significant side effects and long-term toxicity.

Despite the availability of these treatments, Dr. Lerma emphasizes, “Continued research into IgA nephropathy remains crucial to uncovering new opportunities and advancements in our understanding and treatment of patients.”

The Role of APRIL and the 4 Hit Process in IgA Nephropathy

One area of opportunity in IgA nephropathy research is the role of APRIL (A PRoliferation-Inducing Ligand), a cytokine in the tumor necrosis factor (TNF) family, and a key driver of the 4 hit process, which is an important initiating and sustaining factor in IgA nephropathy pathogenesis.

As Dr. Lerma explains, “Targeting APRIL and the 4 hit process represents a potential therapeutic strategy to disrupt IgA nephropathy’s pathogenesis. This is the process in which pathogenic Gd-IgA1 is produced, leading to the synthesis of autoantibodies against Gd-IgA1, immune complex formation, and deposition in the glomerular mesangium, which may lead to kidney injury and can progress to kidney failure.”

Pioneering Research to Transform the Future of Kidney Care

Otsuka Pharmaceutical Development & Commercialization, Inc. is committed to developing and advancing innovative treatments for kidney diseases, including IgA nephropathy. These efforts include clinical research and commercialization of new treatments, patient education and support initiatives to enhance the overall care and management of nephrological conditions.

“Our commitment to nephrology is driven by a deep sense of responsibility to patients facing complex kidney diseases. Through relentless innovation and research, we strive to develop advanced treatments that address high unmet needs, including IgA nephropathy,” says Lina Floren Smith, vice president of nephrology and immunology business at Otsuka. “Beyond treatment, we are dedicated to supporting patients through education and initiatives that enhance overall care, seeking to ensure that they receive the best possible outcomes.”

To stay informed about IgA nephropathy, including the role of APRIL and the latest research advancements, consider signing up for updates at www.discoveraprilinigan.com.

February 2025       21US25EUC0005

*****

Photo Credit: (c) sasirin pamai / Shuttershock

More News

View More
Eli Lilly’s Oral GLP-1 Breakthrough Could Change Everything
Via MarketBeat
Tickers LLY
The Fed Cut Rates: What Now for the S&P 500 and Equity Markets?
Via MarketBeat
Topics ETFs Economy Stocks
Tickers NVDA SNOW SPY WDAY
New Catalysts Build Positive Pressure on Intel Stock
Via MarketBeat
Topics Artificial Intelligence
Tickers ARM INTC TSLA TSM
Bloom Energy Booms on AI Power Demand and Analyst Upgrades
Via MarketBeat
Topics Artificial Intelligence
Tickers AEP AMZN BE MS ORCL
Can Apple’s iPhone 17 and AI Push Its Stock to New Highs?
Via MarketBeat
Topics Artificial Intelligence
Tickers AAPL
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.